Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2,573 | $1,624 | $30,652 | $24,552 |
| - Cash | $5,757 | $5,068 | $3,053 | $3,525 |
| + Debt | $0 | $0 | $3,594 | $0 |
| Enterprise Value | -$3,184 | -$3,444 | $31,193 | $21,027 |
| Revenue | $7,130 | $5,554 | -$3,513 | $5,485 |
| % Growth | 28.4% | 258.1% | -164% | – |
| Gross Profit | $6,284 | $5,554 | -$3,513 | $10,970 |
| % Margin | 88.1% | 100% | 100% | 200% |
| EBITDA | -$3,282 | -$2,174 | -$13,468 | $2,244 |
| % Margin | -46% | -39.1% | 383.4% | 40.9% |
| Net Income | -$7,573 | -$2,858 | -$14,974 | $2,444 |
| % Margin | -106.2% | -51.5% | 426.3% | 44.6% |
| EPS Diluted | -0.005 | -0.003 | -0.022 | 0.004 |
| % Growth | -60.7% | 87.3% | -600% | – |
| Operating Cash Flow | -$4,627 | -$2,649 | -$2,890 | -$4,657 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4,627 | -$2,649 | -$2,890 | -$4,657 |